ProCE Banner Series

Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease

Register now for this CME/CE/CPE-certified interactive workshop series on risk assessment and individualizing therapy for HR-positive/HER2-negative high-risk breast cancer! After the meeting, download the slides and a patient resource, and read expert commentaries on high-risk HR-positive/HER2-negative breast cancer.

To Register: Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AAPA
  | ACPE
  | AMA
  | ANCC
Credits Available

1.0

Who Should Attend

This program is intended for medical oncologists, pharmacists, nurse practitioners, physician associates/physician assistants, nurses, and other healthcare professionals who care for patients with breast cancer.

All Events

Upcoming Events

April

15

2024

Improving Outcomes in Patients with High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease [Open Registration]

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group in SC, Columbia, South Carolina

May

07

2024

Improving Outcomes in Patients with High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease

6:30 PM - 7:30 PM Eastern Time (ET)

Virtual

May

15

2024

Improving Outcomes in Patients with High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease [Open Registration]

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group TX, San Antonio, Texas

Past Events

January

24

2024

Improving Outcomes in Patients with High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease

12:00 PM - 1:00 PM Central Time (CT)

Virtual

Virtual Event | Host Group in TX, Kyle, Texas

February

10

2024

Improving Outcomes in Patients with High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease

7:40 AM - 8:40 AM Central Time (CT)

In-person

Omaha Regency Marriott, 10220 Regency Cir, Omaha, Nebraska 68114

February

28

2024

Improving Outcomes in Patients with High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease [Open Registration]

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group in MD, Baltimore, Maryland

Faculty

ProCE Banner Faculty
Yara Abdou, MD

Assistant Professor
Division of Medical Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

ProCE Banner Faculty
Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

ProCE Banner Faculty
Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader
Breast Oncology Program
UT Health San Antonio 
MD Anderson Cancer Center
San Antonio, Texas

ProCE Banner Faculty
Reshma Mahtani, DO

Chief of Breast Medical Oncology
Medical Oncology
Miami Cancer Institute
Miami, Florida

ProCE Banner Faculty
Jane Lowe Meisel, MD

Associate Professor of Hematology and Medical Oncology
Associate Vice Chair of Faculty Development and Promotions
Winship Cancer Institute at Emory University
Atlanta, Georgia

ProCE Banner Faculty
Michelle Melisko, MD

Clinical Professor of Medicine
Division of Hematology and Oncology
University of California San Francisco
San Francisco, California

ProCE Banner Faculty
Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Topics

Welcome and Baseline Polling

Risk Assessment in HR-Positive/HER2-Negative Breast Cancer

  • Molecular profiling: when to test, how to test, and which patients to test
  • Case discussions

Individualizing Therapy for High-Risk HR-Positive/HER2-Negative

Early Breast Cancer

  • Novel therapies to improve outcomes for high-risk patients in the adjuvant setting
  • Optimal sequencing of targeted therapy with ET and chemotherapy

Individualizing Therapy for High-Risk HR-Positive/HER2-Negative

Metastatic Breast Cancer

  • Novel therapies to improve outcomes for high-risk patients
  • Optimal sequencing of targeted therapy using actionable molecular biomarkers

Strategies for Promoting Adherence and Persistence to Therapies in Patients With High-Risk Breast Cancer

  • Proactive management of adverse events
  • Shared decision-making between HCPs and patients for decisions concerning targeted therapies
  • HCP and patient responsibilities for oral adherence

Audience Question and Answer Session

Concluding Remarks

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Program Overview
This activity is focused on educating the multidisciplinary team on risk assessment and individualizing therapy including strategies to improve adherence to therapy for patients with high-risk HR-positive/HER2-negative breast cancer.

Goal Statement
The goal of this program is to inform and build the necessary skills of target learners to optimize their care of patients with high-risk HR-positive HER2-negative breast cancer. 

Target Audience
This program is intended for medical oncologists, pharmacists, nurse practitioners, physician associates/physician assistants, nurses, and other healthcare professionals who care for patients with breast cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  •  Assess risk in patients with HR+/HER2- EBC and MBC to guide optimal therapy selection for patients with high-risk features in order to improve clinical outcomes
  • Select individualized adjuvant therapies for patients with high-risk, HR+/HER2- EBC based on tumor characteristics, predictive biomarkers, the latest clinical data, approvals, guidelines, and expert recommendations
  • Plan an individualized sequence of therapies for patients with high-risk, HR+/HER2- MBC based on risk assessment, the latest clinical data, approvals, guidelines, and expert recommendations
  • Implement evidence-based management of adverse events associated with CDK4/6 inhibitors for high-risk HR+/HER2- breast cancer
  • Promote adherence to oral targeted therapies in patients with HR+/HER2- breast cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-045-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Lilly.